Fig. 1
From: An animal-free preclinical drug screening platform based on human precision-cut kidney slices
Impact of butaprost, SC-19220 and tamoxifen on TGF-β-induced protein expression in human PCKS. (A, B) PCKS were exposed to 10 ng/mL TGF-β for 48 h (n = 12) in the absence or presence of (C) butaprost (50 µM), (D) SC-19220 (225 µM) or (E) tamoxifen (5 nM); n = 4. Of note, tamoxifen was only present during the final 6 h. Subsequently, Western blotting was performed to study the protein expression of fibronectin (FN) and α-smooth muscle actin (αSMA). Data are presented as mean ± SEM. * p < 0.05, ** p < 0.01. Full-length blots are presented in Supplementary Fig. 1. UNTD, untreated